Patient Registration Articles & Analysis
10 news found
Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies. ...
UpRi is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combinations starting with carboplatin. ...
Food and Drug Administration (FDA). The Phase 3 registrational study is expected to initiate in the first half of 2022. In December 2021, AlloVir initiated a global Phase 3 registrational study of posoleucel for the treatment of AdV infections in adult and pediatric allo-HCT patients. The study is the second registrational trial ...
ByKalaris
“We are very excited to enter into this collaboration with Janssen as we work to transform outcomes for patients,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. ...
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, ...
Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. ...
The workflow requires automated creation of 3D models of a patient’s brain from 2D scans for automatic registration of patients and hologram generation for AR navigation. ...
ByAxial3D
Exclusive to the Cube 4D system is the innovative and touchless VirtuEye photo registration technology that reduces patient registration time to under 40 seconds, and its ease of use enhances the user experience and improves pre-procedure efficiency. Importantly, VirtuEye is designed to collect over 50,000 patient ...
“Our priority as a leading company in the field of intracellular delivery is that patients benefit from innovative medicines made possible through the use of our technology, and we are happy to work with renowned experts who share our vision and will help us achieve our ...
During the study, the majority of patients who developed sepsis already showed high PSP concentration values 24 hours before the diagnosis with current methods. Time being critical with this condition, the outcome for patients could dramatically be improved with a gain of 24 hours. The complete clinical data is currently in preparation for peer reviewed ...